Using hetero-isotherapics in cancer supportive care: the fruit of fifteen years of experience

Background: Chemotherapy, hormone therapy, and new targeted therapies for cancer lead to adverse effects which are often difficult to relieve using classical homeopathy. Besides diminishing the quality of life of the patient, they can force the oncologist to reduce or even to cease treatment prematurely, which represents a loss of opportunity for the patient. Faced with these recurring problems, would the use of homeopathic dilution of chemotherapy, also called hetero-isotherapy, be a suitable response for improving the tolerance of and the adherence to cancer treatment?

Methods: Based on experiments conducted for over 50 years by many authors, we have offered our patients, since 1998, a protocol of hetero-isotherapy chemotherapy starting the day after each cytotoxic infusion. It involves taking a daily dose of a dilution of the chemotherapy used, using the increased dilution technique from 5c to 15c.

Results: We observed a significant decrease in side effects, allergic reactions and late sequelae in the more than 6000 hetero-isotherapic treatments given to some 4000 patients. The better tolerance to chemotherapy and the improvement in quality of life led to an increase in treatment adherence. No interference with chemotherapy was observed. When it was necessary to prescribe another homeopathic medicine, combination with hetero-isotherapy generally improved its effectiveness.

Conclusion: In a large population, followed for over 15 years, we observed that hetero-isotherapics, well tolerated and easy to use, reduced the side effects of chemotherapy, targeted therapy or hormone therapy, and so improve the quality of life of patients.

Keywords

Cancer - Hetero-isotherapy - Homeopathy - Adverse effects - Supportive care

• References

• 1 Rodrigues M. Utilisation des médecines alternatives et complémentaires par les patients en cancérologie. Eurocancer 2010 John Libbey Eurotext; Paris: 2010: 95-96.
• 2 Kassab S., Cummings M., Berkovitz S., van Haselen R., Fisher P. Homeopathic medicines for adverse effects of cancer treatments. Cochrane Database Syst Rev 2009; 2: CD004845.
• 3 Barrière J. Risques et complications potentiels des médecines complémentaires en cancérologie. Eurocancer 2010 John Libbey Eurotext; Paris: 2010: 91-94.
• 4 Bagot JL. Cancer et Homéopathie, rester en forme et mieux supporter les traitements. In: Narayana (ed). Kandern, Germany: Unimedica Publisher, 2012, pp 1–308.
• 5 Bagot J.L. L'homéopathie dans les soins de support en cancérologie. Méneux B. La revue du CEDH. Dumas-Titoulet; Saint-Etienne, France: 2007.
• 6 Lux W. Isopathie der Contagionen. In: Kollmann (ed). Leipzig, 1833.
• 7 Pharmacopée française. Xème édition. Commission nationale de la pharmacopée. In: Maisonneuve (ed). Paris, 1983.
• 8 Lapp C., Wurmser L., Ney J. Mobilisation de l'arsenic fixé chez le cobaye sous l'influence de doses infinitésimales d'arséniate de sodium. Thérapie 1955; 10: 625-638.
• 9 Lapp C., Wurmser L., Kautrelle J. Mobilisation du bismuth fixé chez le cobaye sous l'influence de doses infinitésimales d'un sel de bismuth. Thérapie 1958; 13: 46-55.
• 10 Cazin J.C., Cazin M., Gaborit J.L. et al. A study of the effect of decimal and centesimal dilutions of arsenic on the retention and mobilisation of arsenic in the rat. Hum Toxicol 1987; 6: 315-320.
• 11 Linde K., Jonas W.B., Melchart D., Worku F., Wagner H., Eitel F. Critical review and meta-analysis of serial agitated dilutions in experimental toxicology. Hum Exp Toxicol 1994; 13: 481-492.
• 12 Trepo C., Crapanne J.B., Bissuel F., Cotte L., Rougier P., Schlienger I. Trimethoprim-sulphamethoxazole rechallenge in 20 previously allergic HIV-infected patients after homeopathic desensitation. AIDS 1995; 9: 407-408.
• 13 Bagot J.L. Utilisation des hétéro-isothérapies en cancérologie. La Rev d'Homéopathie 2010; 1: 14-19.
• 14 Bagot J.L. Soins de support en cancérologie. Princ Indic l'homéopathie. 1ère partie: Dermatologie. Méneux B. La revue du CEDH. Dumas-Titoulet; Saint-Etienne, France: 2007: 14-28.
• 15 Bagot J.L. Traitement des manifestations cutanées induites par les inhibiteurs des facteurs de croissance épithéliaux. La Rev d'Homéopathie 2011; 2: 100-105.
• 16 Ferry N., Bernard N., Pozet N. et al. The effect of infinitesimal drug dilutions on the pharmacokinetics of nalidixic acid and atenolol. Br J Clin Pharmacol 1991; 32: 39-44.
• 17 Syndicat National des Pharmaciens Homéopathes. http://www.snph.fr.